NCT07142499 Memory Support System for Older Chinese Americans With Mild Cognitive Impairment
| NCT ID | NCT07142499 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Mild Cognitive Impairment (MCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 7 participants |
| Start Date | 2025-07-29 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 7 participants in total. It began in 2025-07-29 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Memory Support System (MSS) from the Healthy Action to Benefit Independence \& Thinking® (HABIT) Program is an evidence-based, non-pharmacological intervention for mild cognitive impairment (MCI). Despite the clinical benefits and feasibility, the MSS was primarily developed and used with non-Hispanic White, English-speaking adults. Racial/ethnic minority groups are chronically under-enrolled in clinical trials for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) due to lack of linguistically and culturally appropriate adaptation of assessment measures and intervention protocols. The purpose of this research study is to examine whether the MSS from HABIT can help Chinese American older adults with mild thinking and memory problems. Target recruitment is 60 Chinese American adults who are primarily Mandarin- (n=30) and Cantonese-speaking (n=30). Forty participants will participate in the trainer-led day planner training and 20 will participate in self-study of the day planner and receive brain health education. Each participant will also be asked to identify a study partner to participate with them.
Eligibility Criteria
Inclusion criteria: * self-identify as Chinese American; * age 55 and above; * a diagnosis of MCI as confirmed through documented clinical assessment and/or research-based diagnostic criteria; * predominantly Cantonese- or Mandarin-speaking; * able to read and write in Chinese; * visual and auditory acuity adequate for cognitive testing; * willing to complete the assessment measures; * having someone in regular contact to serve as a study partner/informant; * absence or stable use of prescribed memory-enhancing medications within the last 3 months. Exclusion criteria include: * any significant neurologic disease that would impact their participation and completion of the trial; * history of psychiatry disorder (DSM 5 criteria) within the last 12 months; * history of reading or writing disability sufficient to interfere with MSS training; or * concurrent participation in another relevant clinical trial.
Contact & Investigator
Clara Li, PhD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT07142499 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Mild Cognitive Impairment (MCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07142499 currently recruiting?
Yes, NCT07142499 is actively recruiting participants. Contact the research team at clara.li@mssm.edu for enrollment information.
Where is the NCT07142499 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07142499 clinical trial?
NCT07142499 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Clara Li, PhD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 7 participants.